Ultragenyx Pharmaceutical's (RARE) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE - Free Report) in a research report report published on Tuesday,Benzinga reports. The firm currently has a $95.00 price target on the biopharmaceutical company's stock.

Several other research analysts have also issued reports on RARE. Wells Fargo & Company raised their target price on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an "overweight" rating in a research note on Friday. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $116.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, November 6th. JPMorgan Chase & Co. lowered their target price on shares of Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an "overweight" rating for the company in a report on Thursday, November 21st. Canaccord Genuity Group reissued a "buy" rating and issued a $121.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, November 12th. Finally, TD Cowen raised their price target on Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the stock a "buy" rating in a research report on Monday, October 21st. One equities research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $88.46.

Ultragenyx Pharmaceutical Trading Down 0.3 %

Shares of Ultragenyx Pharmaceutical stock traded down $0.12 during midday trading on Tuesday, reaching $43.75. The company had a trading volume of 277,950 shares, compared to its average volume of 779,829. The stock has a fifty day simple moving average of $49.28 and a 200 day simple moving average of $49.37. Ultragenyx Pharmaceutical has a 1-year low of $37.02 and a 1-year high of $60.37. The company has a market capitalization of $4.04 billion, a price-to-earnings ratio of -6.76 and a beta of 0.56.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) EPS for the quarter, beating the consensus estimate of ($1.45) by $0.05. The company had revenue of $139.49 million during the quarter, compared to analysts' expectations of $135.28 million. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. The business's revenue for the quarter was up 42.3% on a year-over-year basis. During the same period last year, the firm earned ($2.23) EPS. Sell-side analysts expect that Ultragenyx Pharmaceutical will post -6.2 earnings per share for the current year.

Insider Transactions at Ultragenyx Pharmaceutical

In other news, CEO Emil D. Kakkis sold 8,273 shares of the firm's stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $50.00, for a total value of $413,650.00. Following the completion of the sale, the chief executive officer now directly owns 2,195,712 shares of the company's stock, valued at $109,785,600. This trade represents a 0.38 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO Howard Horn sold 7,465 shares of Ultragenyx Pharmaceutical stock in a transaction on Thursday, October 10th. The stock was sold at an average price of $52.76, for a total transaction of $393,853.40. Following the transaction, the chief financial officer now directly owns 92,301 shares of the company's stock, valued at approximately $4,869,800.76. This trade represents a 7.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.80% of the stock is currently owned by insiders.

Institutional Trading of Ultragenyx Pharmaceutical

A number of hedge funds have recently modified their holdings of RARE. Millennium Management LLC boosted its stake in Ultragenyx Pharmaceutical by 103.8% in the 2nd quarter. Millennium Management LLC now owns 1,850,734 shares of the biopharmaceutical company's stock valued at $76,065,000 after purchasing an additional 942,529 shares during the period. Alkeon Capital Management LLC boosted its position in shares of Ultragenyx Pharmaceutical by 34.3% in the third quarter. Alkeon Capital Management LLC now owns 3,011,716 shares of the biopharmaceutical company's stock valued at $167,301,000 after acquiring an additional 769,884 shares during the period. Two Sigma Advisers LP grew its stake in shares of Ultragenyx Pharmaceutical by 123.4% in the third quarter. Two Sigma Advisers LP now owns 987,800 shares of the biopharmaceutical company's stock valued at $54,872,000 after acquiring an additional 545,600 shares in the last quarter. Frazier Life Sciences Management L.P. bought a new position in Ultragenyx Pharmaceutical during the second quarter worth about $17,468,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in Ultragenyx Pharmaceutical by 63.8% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 830,375 shares of the biopharmaceutical company's stock worth $34,128,000 after purchasing an additional 323,280 shares in the last quarter. Institutional investors and hedge funds own 97.67% of the company's stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.